Posts

AZ wins EU nod for camizestrant

on

Takeda's zasocitinib proves top-notch for difficult-to-treat psoriasis in Phase 3 update

on

Takeda's AI‑designed psoriasis pill beats Bristol Myers Squibb's Sotyktu in Phase 3 head‑to‑head trial

on

Takeda expects $2.5B hit after Amitiza antitrust verdict, with plans to appeal

on

Innovent declares Phase 3 success for gastric cancer ADC that attracted huge Takeda deal

on

Takeda faces possible $2.5 billion damages in Amitiza pay‑for‑delay case

on

BMS-Hengrui $15B deal, Takeda 4.5K layoffs, and Daiichi's oncology ambition

on

Takeda Restructuring: Over 600 US Layoffs Amid $1.3B Transformation Plan

on

Recent Biotech News: Gene Therapy Advances, Takeda Phase Success, and UK Cancer Funding

on

Takeda Terminates Denali Partnership, Returns DNL593 Dementia Asset Amid Restructuring

on

Takeda Announces Leadership Transition with Julie Kim as New CEO Amid Organizational Changes

on

Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study

on

Takeda Makes Pipeline Cuts and Faces Softer Q2 Sales Due to Generic Competition

on

Takeda and Innovent Forge $1.2B Upfront Oncology Pact for Bispecific and ADC Therapies, Total Deal Valued Up to $11.4B

on

Takeda Expands De Novo Protein Research with Second AI-Driven Collaboration with Nabla Bio

on

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

on

Curtain Closes on Takeda's Cell Therapy Efforts

on

Takeda and Alkermes Detail Strong Clinical Results for Orexin Drugs in Narcolepsy – Head-to-Head Race Accelerates

on

Takeda’s Phase 3 Success Positions Oveporexton (TAK-861) as Potential First Mover in Multibillion-Dollar Narcolepsy Market

on

Takeda's Oveporexton Succeeds in Two Phase III Trials, Paving Way for Narcolepsy Drug Filings

on